Description
CMS-121 is a small-molecule fisetin derivative studied for its activity as a fatty acid synthase (FASN) and acetyl-CoA carboxylase 1 (ACC1) inhibitor. In research models, it is investigated for reducing lipid peroxidation, modulating brain lipid metabolism, and protecting against oxytotic/ferroptotic cell death. Originally developed at the Salk Institute as a candidate for Alzheimer’s disease and age-related cognitive decline, CMS-121 has also been examined in the literature for its effects on diet-induced obesity, type 2 diabetes models, kidney function, and overall geroprotection.
Benefits (Research Focus)
- Studied as a fatty acid synthase (FASN) and ACC1 inhibitor
- Explored for neuroprotective effects in transgenic Alzheimer’s models
- Investigated for reducing lipid peroxidation and ferroptotic cell death
- Examined for cognitive function and memory in aged animal models
- Researched for metabolic effects in obesity and type 2 diabetes models
What Researchers Look At
- Lipid peroxidation and oxytosis/ferroptosis pathways
- Brain acetyl-CoA metabolism and histone acetylation
- Cognitive performance and memory in aged or transgenic AD models
- Hepatic and renal markers of inflammation and aging
- Glucose, insulin, and lipid markers in diabetic models
Quick Specs
- Form: Gelatin Capsule
- Strength: 25 mg/capsule
- Quantity: 30 capsules per bottle
- Excipient: Microcrystalline cellulose (MCC) — pharmaceutical-grade filler
- Storage: Store in a cool, dry, dark place
Identity Basics
- Compound: CMS-121
- Chemical Name: 4-[4-(Cyclopentyloxy)quinolin-2-yl]benzene-1,2-diol
- Chemical Formula: C20H19NO3
- Molecular Weight: 321.38 g/mol
- CAS: 1353224-53-9
Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
